OPKOPKO Health, Inc.

OPKO Health secured $125 million in royalty-backed financing, adding non-dilutive capital while retaining long-term exposure to mazdutide growth in China.

OPKO Health pairs a discounted forward sales multiple with narrowing losses and partnership support, but early-stage clinical risk keeps the investment case balanced.

OPKO Health's 12.4% monthly gain is backed by narrower losses and better margins, though profitability and clinical execution remain key risks.

OPK raises $125 million against mazdutide royalties, gaining non-dilutive capital while retaining longer-term royalty upside.

OPKO Health (OPK) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

OPKO Health, Inc. reported its second-quarter 2026 results on July 27, 2026, with revenue of US$163.58 million and a net loss of US$8.42 million, alongside updated guidance calling for total revenue of US$131 million to US$142 million for the third quarter and US$560 million to US$585 million for full-year 2026. The sharp reduction in quarterly net loss compared with a year earlier, despite mixed revenue trends over the first half, gives investors more detail on how OPKO’s cost structure and...

It posted a beat-and-raise second quarter.

OPK beats Q2 estimates as pharmaceutical growth, Nicoya income and lower costs narrow losses and lift shares pre-market.

Moby summary of OPKO Health, Inc.'s Q2 2026 earnings call

OPKO Health Inc (OPK) reports significant revenue growth in pharmaceuticals and a notable reduction in net loss, despite challenges in diagnostics.

OPKO Health (NASDAQ:OPK) reported a narrower second-quarter loss as gains tied to its diagnostics restructuring and a China commercialization agreement helped lift revenue, while the company continued to increase investment in clinical development programs. Total revenue for the second quarter of 2

While the top- and bottom-line numbers for OPKO Health (OPK) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

OPKO Health (OPK) delivered earnings and revenue surprises of +87.50% and +24.68%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

OPKO Health's growth outlook rests on RAYALDEE, BioReference gains and partnerships, though losses and pipeline risks persist.